The Disease Biology Generative AI Platform for Pharma R&D
We built ASCEND, a science-first GenAI R&D Platform designed to unravel disease biology. ASCEND acts as an AI Assistant/Co-pilot to the preclinical scientist.
ASCEND acts as a co-pilot for scientists, guiding them through the complexities of research. It elevates biology-related decision-making and uncovers novelty while increasing experimental productivity.
ASCEND is powered by a knowledge graph and ontological knowledge base that acts as an evidence map of disease biology.
ASCEND leverages cutting age multi-modal AI to decode, harmonize and elevate the quality of massive amounts of data from scientific literature including closed access, preprints, patents, clinical data, ontological and third-party data source, in-sitro insights, internal pharma data (historical wet lab results) to understand the underlying mechanisms of diseases and the experiments behind those insights.
ASCEND then leverages this data to guide scientists to generate the best ideas and the ideal experimental path to test them.
Why we are different
Robust Data Foundations
Robust structured data foundation to enable scientific versity and explainability
Access to the most comprehensive dataset of closed-access papers
Proprietary and robust ontology knowledge base (OKB)
Proprietary Multimodal biological LLMs and small models focused on understanding experiments from both text and figures (evidence knowledge graph)
Pharma-Focused AI Assistants
Specialized AI assistants with a deep understanding of pharma workflows to unlock value at scale
Deep understanding of workflow across five dimension: scientist, task, TA, stage, & ROI
Multiple specialized assistants
GUI interfaces and collaboration areas
Enterprise-Ready Integrations
Enterprise integrations an readiness to ensure disproportionate value to each pharma
Internal data & Ontologies integrations
Report generation
Customer specific ML models
In-Silico Prediction
Dedicated service team of scientists and engineers to support roll out, adoption and change management
Investors
In the News
Building the Disease Biology Generative AI Platform for Pharma R&D
